• Thurs news: AbbVie Parkinson’s drug. Arch raises $3B biotech fund. Biogen dropping failed Sage tremor drug. AZ gets sought-after Tagrisso OK. Pfizer withdrawing sickle cell med. See more on our front page

Thoughts on Vimovo


<







AZ should never have involved themselves in any conversations about this product.

It never fit their goals and was destined to fail from the start. Esepcially when they put it under M Jackson. Dope.

When any disagreement about taking it on TZ hammered the disenters. So this one belongs to him.

They then went after the smallest part of the market.
 




AZ should never have involved themselves in any conversations about this product.

It never fit their goals and was destined to fail from the start. Esepcially when they put it under M Jackson. Dope.

When any disagreement about taking it on TZ hammered the disenters. So this one belongs to him.

They then went after the smallest part of the market.

TZ knows about as much as my dog about marketing a drug. I knew it was a joke when we went to the "launch meeting". it must have cost all of $50 to put it on. You could tell they were not serious about it.
 








Perhaps someone should have studied the disastrous life of Prevacid Naprapac. The market already didn't respond this this sales gimmick of combining two products, same goes for caduet in cv market.